Uni-Bio Science Group Limited (Hong Kong SAR, China)

Uni-Bio Science Group Limited (HKEX: 0690) is a leading Chinese biopharmaceutical and healthcare company focused on four strategic areas: innovative drugs, high-value generic drugs, medical aesthetics raw materials, and CMO services. The company was established in 2001 and has a long history of operation. With a senior management team that possesses decades of international pharmaceutical industry experience and unique expertise in the Chinese healthcare sector, Uni-Bio Science Group is well-positioned to benefit from the positive changes in the Chinese medical market. The company is dedicated to improving patients' quality of life through innovative therapies and meeting China's demand for high-quality healthcare solutions. The aging population, population growth, and various chronic diseases in China have put significant pressure on the domestic healthcare system. However, Uni-Bio Science Group has established a strong presence and is equipped to address this challenge with its diverse product portfolio and experienced commercial team, achieving several significant milestones. The company has been actively enhancing its operational capabilities to sustain its strong growth momentum. Measures implemented include the establishment of medical and market access departments and increasing market activities to gain market share. Uni-Bio Science Group has achieved excellent results in expanding its product portfolio through strategic partnerships and licensing agreements. Recently, the company formed a strategic alliance with Hong Kong Group, one of the top 50 private enterprises in China. The collaboration includes promoting Uni-Bio Science Group's products through Hong Kong Group's healthcare channels. This alliance further demonstrates the company's broad commercial and research and development expertise, as well as its commitment to ethical and responsible business practices, making it a renowned player in the field of healthcare and a preferred partner for many institutions. The company's innovative business model enables it to maintain competitiveness and develop world-class treatment and healthcare solutions for the benefit of patients nationwide. Uni-Bio Science Group has made and will continue to invest in ensuring supply chain security and accountability, in line with the latest policies and guidelines introduced by the Chinese government. All of the company's production facilities nationwide are equipped with state-of-the-art equipment and have obtained cGMP certification, making Uni-Bio Science Group a high-quality pharmaceutical supplier. With its solid foundation and outstanding achievements in the focused treatment field, Uni-Bio Science Group will continue to strive to become a leader in chronic disease management, providing innovative health products and treatment solutions for China.